Exome Sequence Data of Eight SLC Transporters Reveal That SLC22A1 and SLC22A3 Variants Alter Metformin Pharmacokinetics and Glycemic Control

Abstract excerpt

Background: Type 2 diabetes (T2D) is one of the leading causes of mortality and is a public health challenge worldwide. Metformin is the first-choice treatment for T2D; its pharmacokinetics (PK) is facilitated by members of the solute carrier (SLC) superfamily of transporters, it is not metabolized, and it is excreted by the kidney. Although interindividual variability in metformin pharmacokinetics is documented...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Diabetes Treatment and Management
• Share to Metabolism, Diabetes, and Cancer
• Share to Pancreatic function and diabetes